Fapon Delivers Customized IVD Solutions for the US Market at ADLM 2024
illi News/10273918

Trending...
CHICAGO, July 31, 2024 ~ As the ADLM 2024 (formerly known as the AACC Annual Scientific Meeting & Clinical Lab Expo) kicks off in Chicago, Fapon, a global leading life sciences company, is proud to showcase its innovative IVD total solutions. From July 28 to August 1, attendees will have the opportunity to witness firsthand Fapon's commitment to supporting local partners and delivering customized solutions with advanced innovations and dedicated localization services.

With over two decades of experience in the industry, Fapon has established itself as a pioneer in cutting-edge technology platforms. These include antibody discovery, protein expression, cell fermentation, and protein purification and analysis. In order to continue driving innovation in the field, Fapon has set up an R&D center in Boston focused on molecular diagnostic enzymes and circRNA, as well as an R&D center in San Francisco for next-generation sequencing (NGS) and artificial intelligence (AI). These centers are dedicated to offering innovative diagnostic solutions to the market.

More on illi News
Fapon has also established a deep-rooted presence in the US market through localized strategies that prioritize customer needs and service. With R&D and production facilities set up in the US market, along with a team of dedicated R&D scientists, sales representatives, and technical support experts, Fapon is able to leverage cutting-edge innovations in diagnostic technologies and provide prompt support to local partners backed by a robust supply chain system. Additionally, their commitment to quality is evident through their ISO 13485 and ISO 9001 certifications which guarantee reliable and consistent delivery of superior products.

At ADLM 2024, Fapon is showcasing their comprehensive range of customized IVD solutions. This includes high-performance raw materials, reagent services, and open-system platforms specifically tailored for each client's business needs. Among their new raw material products being showcased are antigens and antibodies for assays related to Alzheimer's Disease (AD), fentanyl testing kits, as well as new products for molecular diagnostics. Fapon also offers reagent solutions for qPCR/RT-qPCR, isothermal amplification, and NGS library preparation, with a focus on enzyme innovation using AI-based enzyme engineering. Their portfolio also includes high-performance raw materials for influenza testing, particularly for H5N1, and products for cardiac markers to meet the specific demands of the US market.

More on illi News
In addition to their existing CLIA analyzer platforms, Fapon has expanded their offerings with the launch of two new additions: Shine i6000 with a throughput of 600T/H and Shine i3000 with a throughput of 300T/H. These new additions provide customers with more options for throughput choices. To complement their range of analyzers, Fapon has also introduced two cutting-edge and fully automated molecular diagnostic systems - Ideal 30 for human diagnostics and Nous 30V for veterinary diagnostics. These innovative platforms are designed to accelerate product development processes and offer customized options for their valued customers.

Looking towards the future, Fapon remains committed to providing innovative IVD solutions and refining their product offerings to meet the ever-evolving needs of the US IVD market segment. With their deep-rooted presence in the US market and dedication to cutting-edge research and development, Fapon is poised to continue leading the way in delivering customized IVD solutions that meet the highest standards of quality and performance.
Filed Under: Business
Show All News | Disclaimer | Report Violation

0 Comments

Latest on illi News